Table 3.

Patient characteristics and their associations with the prevalence of self-report of missing a visit with an HIV provider in the prior month, among persons who had a scheduled visit with an HIV provider in the prior month and who were enrolled in a NIDA-funded cohort and completed a survey during the COVID-19 pandemic, 11 May 2020–15 February 2021.

Covariate	Crude Prevalence Ratio	Adjusted Prevalence Ratio
Age, 1-year increment	0.98 (0.96, 1.00)	0.99 (0.97, 1.01)
Male sex	1.25 (0.71, 2.20)	1.18 (0.67, 2.07)
Race/ethnicity, ref Black, non-Hispanic
White, non-Hispanic	0.95 (0.54, 1.66)	0.96 (0.56, 1.63)
Hispanic	0.92 (0.63, 1.34)	0.95 (0.63, 1.45)
Other, non-Hispanic	1.05 (0.56, 1.98)	0.80 (0.40, 1.61)
Unstable housing	1.45 (0.93, 2.25)	1.32 (0.83, 2.10)
Employment, ref Employed
Unstable employment	0.79 (0.52, 1.20)	0.61 (0.38, 0.99)
Unemployed	1.10 (0.79, 1.54)	0.79 (0.52, 1.20)
Food insecurity	1.47 (1.09, 1.99)	1.31 (0.95, 1.82)
Moderate-to-severe anxiety	1.45 (1.03, 2.04)	1.13 (0.77, 1.64)
Resiliency, ref Normal
Low	1.59 (1.12, 2.26)	1.43 (0.99, 2.07)
High	0.78 (0.51, 1.20)	0.90 (0.57, 1.42)
Disruption in mental health care	1.38 (1.00, 1.90)	1.23 (0.87, 1.72)
Recent drug use
Smoking	1.73 (1.28, 2.35)	1.50 (1.09, 2.08)
Hazardous alcohol use	1.51 (1.01, 2.24)	1.15 (0.74, 1.78)
Cocaine	1.78 (1.22, 2.59)	1.31 (0.85, 2.03)
Opioids	1.24 (0.67, 2.30)	0.88 (0.44, 1.77)
Cannabis	1.61 (1.18, 2.19)	1.32 (0.92 1.89)
Substance use treatment	0.85 (0.55, 1.31)	0.85 (0.39, 1.86)
Disruptions to substance use treatment	1.23 (0.54, 2.80)	1.06 (0.46, 2.40)
Current opioid agonist therapy	1.28 (0.65, 2.52)	1.11 (0.43, 2.87)
Disruptions to opioid agonist therapy	1.13 (0.34, 3.80)	1.20 (0.32, 4.46)
≥ “Much” disruptions of COVID-19 pandemic	1.26 (0.86, 1.83)	1.18 (0.79, 1.75)
Substantial worry due to the pandemic	1.03 (0.72, 1.47)	0.88 (0.59, 1.31)